로딩 중…
지수 로딩 중…
제놀루션
225220· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,370-6.36%
2026-06-19
Price Chart
제놀루션-44.20%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 26.29B KRW |
| Revenue | 9.82B KRW |
| Net Income | -2.60B KRW |
| Total Assets | 94.35B KRW |
| Net Assets | 68.32B KRW |
| Employees | 86 |
| Value | |
| P/B | 0.38x |
| P/S | 2.68x |
| FCF Yield | -27.79% |
| Profitability | |
| ROE | -3.80% |
| ROA | -2.75% |
| Op. Margin | -9.36% |
| Revenue Growth | 20.16% |
| Financial Health | |
| Debt Ratio | 138.09% |
| Total Debt | 9.00B KRW |
| FCF | -7.31B KRW |
| Cash | 18.22B KRW |
| Current Ratio | 1.30x |
| Dividend | |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | -44.20% |
| 1M Return | -23.89% |
| From 52W High | -51.59% |
| 1Y MDD | -47.10% |
| Trading | |
| Volume | 121,582 shares |
| Foreign Own. | 1.61% |
| Per Share | |
| EPS | -467 KRW |
| BPS | 3,817 KRW |
Company Info
The company, established in 2006, commenced manufacturing biological products and was listed on KOSDAQ in 2020. It operates in two main sectors: precision medicine, selling nucleic acid extraction reagents and automated equipment, and green bio, developing animal pharmaceuticals and crop protection agents using RNA interference technology. In 2024, it received approval for Honeyguard-R Solution, the world's first gene therapy for honeybee Sacbrood disease. The company is further expanding its business through R&D for Nosema disease treatments and eco-friendly RNA pesticides. Genolution is headquartered in Gangseo-gu, Seoul Metropolitan City.